IBO

ROCHESTER, N.Y., Sept. 16, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE:DSS) ("DSS" or the "Company") today announced that Zoar Limited ("Zoar" or "PubCo") has filed a Registration Statement on Form F-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") in connection with the previously announced proposed business combination (the "Business Combination") involving Impact Biomedical Inc. (NYSE:IBO) ("Impact"), Zoar and certain related parties. DSS is a significant stockholder of Impact Biomedical, and the filing represents an important step in Impact’s proposed Business Combination with Zoar. "We are pleased to see Impact reach this important milestone in

HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (NYSE:IBO) (the "Company" or "Impact") announced that a Form F-4 registration statement (the "Registration Statement") was filed with the U.S. Securities and Exchange Commission (the "SEC") on Thursday, September 10, 2026, by Zoar Limited ("PubCo") in connection with the previously announced business combination (the "Business Combination") with, among others, PubCo and Zoar Labs Limited (f/k/a Dr. Ashley’s Bio Labs Limited) ("Zoar Labs"), which includes Impact’s preliminary proxy statement. The F-4 Registration Statement is available through the SEC’s website at www.sec.gov under the name "Zoar Limited". The management of

8-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the "Company" or "Impact") dated September 11, 2026. The original press release incorrectly stated that Impact stockholders would receive one (1) share of Zoar Limited for every four (4) shares of Impact Common Stock (defined below). The correct exchange ratio, as set forth in the Merger and Share Exchange Agreement as Exhibit 2.1 to the current report on Form 8-K dated June 23, 2025 (Accession No.0001641172-25-016002), is one (1) share of Zoar Limited for every one (1) share of Impact Commo

HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (the "Company") today announced that the Company's Board of Directors has approved a 1 for 12.62 reverse stock split of the Company's issued and outstanding common stock, par value $0.001 per share (the "Common Stock"). The reverse stock split will become effective at 12:01 a.m., Eastern Time, on September 23, 2026. Starting with the opening of trading on that date, the Company’s Common Stock will continue to trade on the NYSE American Exchange under the ticker symbol "IBO" and will trade under a new CUSIP number to be assigned in connection with the reverse stock split. On December 30, 2025, the Company's stockholders a

10-Q - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

10-Q - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

144 - IMPACT BIOMEDICAL INC. (0001834105) (Subject)

S-8 POS - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

S-8 POS - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

HOUSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026, includes an audit opinion from Grassi & Co., CPAs, P.C. that contains a "going concern" qualification. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph and does not represent any change or amendment to the Company's financial statements for the year ended December 31, 2025. Again, this announcement does not represent any change or amendment to the Company's finan

4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

10-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

8-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)

DEF 14C - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

PRE 14C - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

10-Q - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

8-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

8-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

DEF 14A - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

DEF 14C - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

PRE 14C - IMPACT BIOMEDICAL INC. (0001834105) (Filer)

HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled "Composition and Method of Controlling Infectious Diseases with Functional Fragrances," developed within IBO's 3F™ technology platform. This patent relates to unique composition and method for controlling infectious diseases. It includes compositions and formulations of constituents found in plants and fragrances produced by plants, with potential application as an antibacterial or antiviral agent. This patent will expire on December 7, 2038. This expands Impact Biomedical's 3F™ patent estate which include